These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18311112)

  • 21. Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.
    Roy M; Buehler DG; Zhang R; Schwalbe ML; Baus RM; Salamat MS; Lloyd RV; Rosenbaum JN
    Endocr Pathol; 2019 Mar; 30(1):35-42. PubMed ID: 30523500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment.
    Gilani S; Guo CC; Li-Ning EM; Pettaway C; Troncoso P
    Hum Pathol; 2017 Jun; 64():186-190. PubMed ID: 28159676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parallel determination of NeuroD1, chromogranin-A, KI67 and androgen receptor expression in surgically treated prostate cancers.
    Cindolo L; Cantile M; Franco R; Chiodini P; Schiavo G; Forte I; Zlobec I; Salzano L; Botti G; Gidaro S; Terracciano L; Cillo C
    Int Braz J Urol; 2011; 37(1):57-66. PubMed ID: 21385481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells.
    Gupta A; Wang Y; Browne C; Kim S; Case T; Paul M; Wills ML; Matusik RJ
    Prostate; 2008 Jan; 68(1):50-60. PubMed ID: 18004726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiation of medullary thyroid cancer by C-Raf-1 silences expression of the neural transcription factor human achaete-scute homolog-1.
    Chen H; Carson-Walter EB; Baylin SB; Nelkin BD; Ball DW
    Surgery; 1996 Aug; 120(2):168-72; discussion 173. PubMed ID: 8751579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer.
    Nordin A; Wang W; Welén K; Damber JE
    Prostate; 2013 May; 73(6):657-67. PubMed ID: 23129424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence.
    Ito T; Yamamoto S; Ohno Y; Namiki K; Aizawa T; Akiyama A; Tachibana M
    Oncol Rep; 2001; 8(6):1221-4. PubMed ID: 11605036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells.
    Danza G; Di Serio C; Rosati F; Lonetto G; Sturli N; Kacer D; Pennella A; Ventimiglia G; Barucci R; Piscazzi A; Prudovsky I; Landriscina M; Marchionni N; Tarantini F
    Mol Cancer Res; 2012 Feb; 10(2):230-8. PubMed ID: 22172337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Achaete-scute homolog 1 as a marker of poorly differentiated neuroendocrine carcinomas of different sites: a validation study using immunohistochemistry and quantitative real-time polymerase chain reaction on 335 cases.
    La Rosa S; Marando A; Gatti G; Rapa I; Volante M; Papotti M; Sessa F; Capella C
    Hum Pathol; 2013 Jul; 44(7):1391-9. PubMed ID: 23375646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors.
    Genitsch V; Zlobec I; Seiler R; Thalmann GN; Fleischmann A
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphometric analysis of CC10-hASH1 transgenic mouse lung: a model for bronchiolization of alveoli and neuroendocrine carcinoma.
    Linnoila RI; Sahu A; Miki M; Ball DW; DeMayo FJ
    Exp Lung Res; 2000 Dec; 26(8):595-615. PubMed ID: 11195458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Neuroendocrine differentiation in prostate cancer].
    Wu CY; Na YQ; Yao JL; di Sant'Agnese PA; Huang JT
    Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):565-7. PubMed ID: 17134555
    [No Abstract]   [Full Text] [Related]  

  • 33. [Role of neuroendocrine cells in prostate cancer progression].
    Sciarra A; Innocenzi M; Ravaziol M; Minisola F; Alfarone A; Cattarino S; Panebianco V; Buonocore V; Gentile V; Di Silverio F
    Urologia; 2011; 78(2):126-31. PubMed ID: 21574145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype].
    Bonkhoff H; Fixemer T
    Urologe A; 2004 Jul; 43(7):836-42. PubMed ID: 15048555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroendocrine differentiation in the progression of prostate cancer.
    Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
    Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
    Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS
    Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer.
    Jeetle SS; Fisher G; Yang ZH; Stankiewicz E; Møller H; Cooper CS; Cuzick J; Berney DM;
    Virchows Arch; 2012 Aug; 461(2):103-7. PubMed ID: 22767265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical study of the neural development transcription factors (TTF1, ASCL1 and BRN2) in neuroendocrine prostate tumours.
    Rodríguez-Zarco E; Vallejo-Benítez A; Umbría-Jiménez S; Pereira-Gallardo S; Pabón-Carrasco S; Azueta A; González-Cámpora R; Espinal PS; García-Escudero A
    Actas Urol Esp; 2017 Oct; 41(8):529-534. PubMed ID: 28285791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
    Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
    J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
    Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
    Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.